List view / Grid view


Applications of solid-state NMR spectroscopy to pharmaceuticals

21 February 2013 | By Eric Munson, Patrick DeLuca Endowed Professor in Pharmaceutical Technology, Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky

Solid-state NMR spectroscopy (SSNMR) has emerged as an extremely powerful analytical technique for the characterisation of pharmaceuticals[1-5]. Despite its capability, SSNMR is still not used ubiquitously in the pharmaceutical industry. Several factors contribute to this, including cost and analysis time, but two of the major reasons are understanding the full…

Extracellular microRNA: the promises for the diagnostics of multiple diseases

21 February 2013 | By Andrey Turchinovich and Barbara Burwinkel, German Cancer Research Center

This mini-review aims to summarise recent advances in the field of molecular diagnostic of diseases using extracellular circulating miRNA in biological fluids. We will also discuss obstacles in developing miRNAs as circulating biomarkers as well as the potential future of the field.

Getting to grips with drug resistance in the human protein kinase superfamily

21 February 2013 | By Patrick A Eyers, Department of Oncology, Sheffield Cancer Research Centre, University of Sheffield

Protein kinases represent a vast, partially untapped resource of drug targets for therapeutic intervention in human disease. The remarkable success of the tyrosine kinase inhibitor Imatinib, which is now the first-line therapy in Philadelphia-positive tyrosine kinase inhibitor Imatinibhas galvanised biomedical researchers in an attempt to repeat the landmark success of…

Improving the quantitation of live antigens used to produce rabbit generated serotype specific antiserum

21 February 2013 | By Michael J. Miller, President, Microbiology Consultants, LLC, Silvia Fragoeiro, Ananthi Ramachandran and Paul van Empel MSD Animal Health

This is the first paper in our continuing series on Rapid Microbiological Methods (RMM) that will appear in European Pharmaceutical Review during 2013. Flow cytometry represents one of a variety of viability-based RMM technologies that are currently available to the pharmaceutical industry. In flow cytometry, individual particles are counted as…

Practical Workshop – Biochemical Assays for Screening

21 February 2013 | By Sheraz Gul, Head of Biology at European ScreeningPort, Hamburg, Germany

Recent years have witnessed an expansion in the disciplines encompassing drug discovery outside the pharmaceutical industry. This is most notable with a significant number of universities worldwide that now host infrastructure such as compound libraries and automated screening centres[1-3]. An archetypal small molecule drug discovery project will aim to identify…

The evolution of the Contract Research Organisation and the future of the pharmaceutical industry

20 February 2013 | By , ,

This article discusses how the pharmaceutical industry can leverage its competencies in outsourcing to accelerate time to market, improve quality and increase innovation at all stages of the drug discovery and development process. The pharmaceutical industry is being battered by a perfect storm of not just one but three major…

Intelligent Process Condition Monitoring for industrial tablet coating operation

18 December 2012 | By Jun Huang, Saly Romero-Torres, Liam Ryan and Mojgan Moshgbar, Pfizer Inc

This paper presents a feasibility study to develop an Intelligent Process Condition Monitoring (IPCM) system for providing a real time ‘health check’ for the tablet coating process in drug product manufacturing. The study fits well under the framework of Intelligent based Manufacturing (IbM) initiated at Pfizer, and intends to move…

Future trends in drug discovery technology

18 December 2012 | By Terry McCann, TJM Consultancy

The average cost to a major pharmaceutical company of developing a new drug is over USD 6 billion1. Herper1 observes that the pharmaceutical industry is gripped by rising failure rates and costs, and suggests that the cost of new drugs will be reduced by new technologies and deeper understanding of…

A new vision of drug discovery and development

18 December 2012 | By D. Lansing Taylor, Director, University of Pittsburgh Drug Discovery Institute and Allegheny Foundation Professor of Computational and Systems Biology, University of Pittsburgh School of Medicine

The pharmaceutical industry has experienced a decade of turbulence driven by the ‘patent cliff’ as major revenue generators are lost to generic status, coupled to the absence of a sustainable pipeline of drug candidates in development that have a good chance of being approved and launched. It is generally agreed…

MS-based methods for detection, quantitation and localisation of pharmaceuticals and metabolites in biological samples

18 December 2012 | By Tyler Greer, Department of Chemistry, University of Wisconsin-Madison and Lingjun Li, Department of Chemistry & School of Pharmacy, University of Wisconsin-Madison

Mass spectrometry is a powerful, multi-faceted technique capable of analysing pharmaceuticals and their metabolites in biological matrices. Although it is more commonly applied to proteins, peptides and lipids, an increasing number of studies use mass spectrometry based techniques to detect, quantitate and localise pharmaceuticals and their metabolites. The availability of…

Found in translation

18 December 2012 | By Theresa LaVallee, Senior Director, Translational Medicine Oncology, MedImmune

The development of biologic therapies has significantly shifted the treatment paradigm in medicine, particularly in oncology. Groundbreaking research over the past 20 years has sparked new ways of thinking about disease pathology and opened the door for novel targeted therapies that have truly revolutionised medical care. In more recent years,…